Model
Owns Zava (UK, Germany, France, Ireland) and Eucalyptus/Juniper. In the US, a Novo Nordisk partner after settling a compounding dispute.
Pricing
US Wegovy pricing through telehealth partners was set at $599/month at the April 2025 partnership announcement.
Funding
Public company.
Scale
FY2025 revenue $2.35bn, up 59%, with marketing at 39% of revenue. Q2 2026 revenue $753.2m, up 38%, 2.891m subscribers. Gross margin fell from 79% to 74% to 64% as it moved from compounded to branded GLP-1 supply, the clearest read-across for what branded-only European markets do to margin.
Regulatory history
HHS asked the DOJ to investigate Hims over a compounded version of the Wegovy pill (February 2026); Novo Nordisk accused it of "illegal mass compounding" and the two settled on 9 March 2026, with Hims selling Novo product at the same prices as other telehealth firms and dropping compounded promotion.
In 2026
Completed the Eucalyptus acquisition on 2 June 2026. CEO Andrew Dudum called the Wegovy pill launch "staggering" on the Q2 2026 call and framed the strategy as moving beyond single-drug dispensing toward longitudinal multi-condition care.
Markets
United States, United Kingdom, Germany, France, Ireland, Australia.
Covered in this atlas: Germany, France, United Kingdom, Ireland.